MRX Fundamental Analysis - MISTER SPEX SE

Name: MISTER SPEX SE (MRX) Stock
Brand: MISTER SPEX SE
Rating: 3.5 (3 reviews)

Fundamental Rating

Taking everything into account, MRX scores 2 out of 10 in our fundamental rating. MRX was compared to 49 industry peers in the Specialty Retail industry. MRX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, MRX is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MRX has reported negative net income.

In the past year MRX has reported a negative cash flow from operations.

In the past 5 years MRX always reported negative net income.

MRX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -48.65%, MRX is doing worse than 91.07% of the companies in the same industry.

Looking at the Return On Equity, with a value of -130.40%, MRX is doing worse than 87.50% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-48.65%
ROE	-130.4%
ROIC	N/A

ROA(3y)-27.31%

ROA(5y)-20%

ROE(3y)-57.09%

ROE(5y)-43%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MRX has a Gross Margin of 52.97%. This is in the better half of the industry: MRX outperforms 78.57% of its industry peers.

In the last couple of years the Gross Margin of MRX has remained more or less at the same level.

The Profit Margin and Operating Margin are not available for MRX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	52.97%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.74%

GM growth 5Y0.94%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MRX does not have a ROIC to compare to the WACC, probably because it is not profitable.

MRX has more shares outstanding than it did 1 year ago.

MRX has more shares outstanding than it did 5 years ago.

The debt/assets ratio for MRX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -2.30, we must say that MRX is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -2.30, MRX is not doing good in the industry: 82.14% of the companies in the same industry are doing better.

A Debt/Equity ratio of 0.82 indicates that MRX is somewhat dependend on debt financing.

MRX's Debt to Equity ratio of 0.82 is on the low side compared to the rest of the industry. MRX is outperformed by 64.29% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.82
Debt/FCF	N/A
Altman-Z	-2.3

ROIC/WACCN/A

WACC5.08%

2.3 Liquidity

MRX has a Current Ratio of 2.21. This indicates that MRX is financially healthy and has no problem in meeting its short term obligations.

With an excellent Current ratio value of 2.21, MRX belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.

A Quick Ratio of 1.57 indicates that MRX should not have too much problems paying its short term obligations.

With an excellent Quick ratio value of 1.57, MRX belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.21
Quick Ratio	1.57

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -64.99%.

MRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.09%.

Measured over the past years, MRX shows a quite strong growth in Revenue. The Revenue has been growing by 9.25% on average per year.

EPS 1Y (TTM)-64.99%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%31.82%

Revenue 1Y (TTM)-13.09%

Revenue growth 3Y3.73%

Revenue growth 5Y9.25%

Sales Q2Q%-21.77%

3.2 Future

The Earnings Per Share is expected to grow by 22.29% on average over the next years. This is a very strong growth

Based on estimates for the next years, MRX will show a quite strong growth in Revenue. The Revenue will grow by 11.67% on average per year.

EPS Next Y55.11%

EPS Next 2Y29.79%

EPS Next 3Y22.29%

EPS Next 5YN/A

Revenue Next Year-14.56%

Revenue Next 2Y-5.85%

Revenue Next 3Y-2.45%

Revenue Next 5Y11.67%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRX. In the last year negative earnings were reported.

Also next year MRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MRX's earnings are expected to grow with 22.29% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y29.79%

EPS Next 3Y22.29%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MRX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MISTER SPEX SE

FRA:MRX (11/7/2025, 7:00:00 PM)

1.42

+0.04 (+2.9%)

Chartmill FA Rating

GICS SectorConsumer Discretionary

GICS IndustryGroupConsumer Discretionary Distribution & Retail

GICS IndustrySpecialty Retail

Earnings (Last)05-08 2024-05-08/amc

Earnings (Next)N/A N/A

Inst Owners23.48%

Inst Owner ChangeN/A

Ins Owners3.98%

Ins Owner ChangeN/A

Market Cap49.77M

Revenue(TTM)195.63M

Net Income(TTM)-79.22M

Analysts77.5

Price Target4.42 (211.27%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)14.75%

PT rev (3m)5.61%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)11.11%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0.57%

Revenue NY rev (3m)-2.87%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.25
P/FCF	N/A
P/OCF	N/A
P/B	0.82
P/tB	0.89
EV/EBITDA	N/A

EPS(TTM)-2.41

EYN/A

EPS(NY)-0.48

Fwd EYN/A

FCF(TTM)-0.52

FCFYN/A

OCF(TTM)-0.38

OCFYN/A

SpS5.58

BVpS1.73

TBVpS1.59

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-48.65%
ROE	-130.4%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	52.97%
FCFM	N/A

ROA(3y)-27.31%

ROA(5y)-20%

ROE(3y)-57.09%

ROE(5y)-43%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.74%

GM growth 5Y0.94%

F-Score4

Asset Turnover1.2

Health

		Industry Rank	Sector Rank
Debt/Equity	0.82
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	9.09%
Cap/Sales	2.45%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.21
Quick Ratio	1.57
Altman-Z	-2.3

F-Score4

WACC5.08%

ROIC/WACCN/A

Cap/Depr(3y)41.44%

Cap/Depr(5y)71.03%

Cap/Sales(3y)6.28%

Cap/Sales(5y)7.09%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-64.99%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%31.82%

EPS Next Y55.11%

EPS Next 2Y29.79%

EPS Next 3Y22.29%

EPS Next 5YN/A

Revenue 1Y (TTM)-13.09%

Revenue growth 3Y3.73%

Revenue growth 5Y9.25%

Sales Q2Q%-21.77%

Revenue Next Year-14.56%

Revenue Next 2Y-5.85%

Revenue Next 3Y-2.45%

Revenue Next 5Y11.67%

EBIT growth 1Y-62.51%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year95.08%

EBIT Next 3Y31.32%

EBIT Next 5Y29.96%

FCF growth 1Y34.59%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-46.81%

OCF growth 3YN/A

OCF growth 5YN/A

MISTER SPEX SE / MRX.DE FAQ

What is the fundamental rating for MRX stock?

ChartMill assigns a fundamental rating of 2 / 10 to MRX.DE.

What is the valuation status of MISTER SPEX SE (MRX.DE) stock?

ChartMill assigns a valuation rating of 1 / 10 to MISTER SPEX SE (MRX.DE). This can be considered as Overvalued.

Can you provide the profitability details for MISTER SPEX SE?

MISTER SPEX SE (MRX.DE) has a profitability rating of 1 / 10.

Can you provide the financial health for MRX stock?

The financial health rating of MISTER SPEX SE (MRX.DE) is 3 / 10.

What is the expected EPS growth for MISTER SPEX SE (MRX.DE) stock?

The Earnings per Share (EPS) of MISTER SPEX SE (MRX.DE) is expected to grow by 55.11% in the next year.

MISTER SPEX SE (MRX.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MISTER SPEX SE / MRX.DE FAQ

What is the fundamental rating for MRX stock?

What is the valuation status of MISTER SPEX SE (MRX.DE) stock?

Can you provide the profitability details for MISTER SPEX SE?

Can you provide the financial health for MRX stock?

What is the expected EPS growth for MISTER SPEX SE (MRX.DE) stock?